

Division of Signal Transduction Therapy

Standard Operating Procedure

Preparation of active CLK1 [129 - 484]

Enzyme description:- CLK1 [129 - 484]

Clone number:- DU 27352

Source:- Recombinant

Expression system:- *E.coli*

Tag:- N-terminal GST

Purification method:- GSH Sepharose

Calculated molecular mass:-

Monoisotopic 68, 555.83 daltons

Average Mass 68, 600.03 daltons

[cysteines reduced, methionines have not been oxidised]

Theoretical pI:- 6.57

Purity:- >80 %

Activation protocol:- Constitutively active

Enzyme storage buffer:-

50 mM Tris-HCl pH 7.5, 270 mM Sucrose, 150 mM NaCl, 0.1 mM EGTA,
0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 1 mM benzamidine, 0.2 mM PMSF

Storage temperature:- -70 °C

Assay:- Standard filter binding assay

Assay buffer:-

50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 10 mM DTT, 2 mM manganese chloride

Substrate:-

RNRYRDVSPFDHSR

Final concentration: 300 uM

Division of Signal Transduction Therapy

Clone Data Sheet

CLK1 [129 - 484]

Protein CLK1 [129 - 484]

Clone number DU 27352

Species Human

Accession number NM_004071.3

Tags N-terminal GST

Bacterially expressed protein MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELG
LEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAIEISMLEGA
VLDIRYGVSR IAYS KDFETLKVDFLSKLP EMLKMFEDRLCHKTYLNGDH
VTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDKYLKSS
KYIAWPLQGWQATFGGGDHPPKSDLEVL FQGPLGSMHGKSHRRKRTRSV
EDDEEGHLICQSGDVLSARYEIVDTLGE GAFGKVVECIDHKAGGRHVAV
KIVKNVDRYCEAARSEIQVLEHLN TTPNSTFR CVQMLEWFEHHGHICI
VFELLGLSTYDFIKENGF L PFRLDHIRKMAYQICKSVN FLHSNKLTHTD
LKPENILFVQSDYTEAYNPKIKRDERTLINPDIKV VDFGSATYDDEHHS
TLVSTRHYRAPEVILALGWSQPCDVWSIGCILIEYYLGFTVFP THDSKE
HLAMMERILGPLPKHMIQKTRKRKYFHHDRLD WDEHSSAGRYVSR RCKP
LKEFMLSQDVEHERLFDLIQKMLEYDPAKRITLREALKHPFFDLLKKS I

Native sequence Amino acids H129 – I484 (end) of human CLK1.
Residue H233 of the fusion protein is equivalent to H129 of the native enzyme. The GST tag is located at residues 1 – 220.

Protease cleavage PreScission (LEVL FQGP) residues 221 - 228

Cloning sites *Bam*H1 and *Not*1 sites of pGEX6P-1

Division of Signal Transduction Therapy

Nucleotide Sequence Of Insert

ggatccatgCATGGGAAGAGTCACCGAAGGAAAAGAACCAGGAGTGTAGAGGATGATGA
GGAGGGTCACCTGATCTGTCAGAGTGGAGACGTACTAAGTGCAAGATATGAAATTGTTG
ATACTTTAGGTGAAGGAGCTTTTGGAAAAGTTGTGGAGTGCATCGATCATAAAGCGGGA
GGTAGACATGTAGCAGTAAAAATAGTTAAAAATGTGGATAGATACTGTGAAGCTGCTCG
CTCAGAAATACAAGTTCTGGAACATCTGAATACAACAGACCCCAACAGTACTTTCCGCT
GTGTCCAGATGTTGGAATGGTTTGGAGCATCATGGTCACATTTGCATTGTTTTTGAACTA
TTGGGACTTAGTACTTACGACTTCATTAAGAAAATGGTTTTCTACCATTTGACTGGA
TCATATCAGAAAGATGGCATATCAGATATGCAAGTCTGTGAATTTTTTGCACAGTAATA
AGTTGACTCACACAGACTTAAAGCCTGAAAACATCTTATTTGTGCAGTCTGACTACACA
GAGGCGTATAATCCCAAATAAAACGTGATGAACGCACCTTAATAAATCCAGATATTAA
AGTTGTAGACTTTGGTAGTGCAACATATGATGACGAACATCACAGTACATTGGTATCTA
CAAGACATTATAGAGCACCTGAAGTTATTTTAGCCCTAGGGTGGTCCCAACCATGTGAT
GTCTGGAGCATAGGATGCATTCTTATTGAATACTATCTTGGGTTTACCGTATTTCCAAC
ACACGATAGTAAGGAGCATTTAGCAATGATGGAAAGGATTCTTGGACCTCTACCAAAC
ATATGATACAGAAAACCAGGAAACGTAATATTTTACCACGATCGATTAGACTGGGAT
GAACACAGTTCTGCCGGCAGATATGTTTTCAAGACGCTGTAAACCTCTGAAGGAATTTAT
GCTTTCTCAAGATGTTGAACATGAGCGTCTCTTTGACCTCATTTCAGAAAATGTTGGAGT
ATGATCCAGCCAAAAGAATTACTCTCAGAGAAGCCTTAAAGCATCCTTTCTTTGACCTT
CTGAAGAAAAGTATAtagcgggccgc